Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UCN 01

Drug Profile

UCN 01

Alternative Names: 7-Hydroxystaurosporine; KRX-0601; KW-2401; NSC-638850; UCN-01; UCN-02

Latest Information Update: 22 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko
  • Class Antineoplastics
  • Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors; Checkpoint kinase 1 inhibitors; Phosphotransferase inhibitors; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Lymphoma; Malignant melanoma; Myelodysplastic syndromes; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 May 2018 NCT00003289 - tagged source and CTP in KDM
  • 04 Apr 2008 Discontinued - Phase-I for Acute myeloid leukaemia in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top